Leo I Gordon

Feinberg School of Medicine, Feinberg Clinical, Medicine, Hematology Oncology Division

• Home
• Expert Overview
• Profile
• Publications
• Grants
• Patents
• Similar Experts
• Journals
• Trends
• Institutional Network
• Coauthor Network
• Research Network
• Curriculum Vitae

Leo I Gordon

• Schools & Departments
  Feinberg School of Medicine
  
  Feinberg Clinical
  
  Medicine, Hematology Oncology Division
  
  

  Current Appointments:

  Professor; Medicine, Hematology Oncology Division; Feinberg School of Medicine

  
  
  

Apoptosis, Bone Marrow Transplantation, Cancer Biology, Cancer: Blood (leukemia, lymphomas), Hodgkin's Disease, Leukemia, Lymphomas, Monoclonal Antibodies, Non-Hodgkin's Lymphoma, Stem Cells, Transplantation

312/695-4546

41 Grants

This is a chronological listing of grants held by this researcher, with the most recent listed first. New grants appear in this list weekly and contribute related to their fingerprint profile. The source of grants for this application comes directly from your institution.

• 1.

  Leo Gordon; Hugh Anderson; Brandon Miller

  Prot# SGN35-005: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of SGN-35 (brentuximab vedotin) and Best Supportive Care (BSC) versus Placebo and BSC in the Treatment of Patients at High Risk of Residual Hodgkin Lymphoma (HL) Following Autologous Stem Cell Transplant (ASCT)

  12/15/2012 - 12/15/2015

  Document ID: SGN35-005

  Sponsor: Seattle Genetics, Inc.

• 2.

  Leo Gordon

  MAP Kinase Signaling in Lymphoma: A Novel Therapeutic Paradigm

  8/10/2012 - 5/31/2013

  Document ID: 6143764/RFS2013035//1R01CA164311-01

  Sponsor: University of Massachusetts Medical School

• 3.

  Leo Gordon

  Prot# GAO4915g: A Phase II, Open-Label, Multicenter Study of Efficacy, Safety, And Biomarkers in Patients With Previously Untreated Advanced Diffuse Large B-cell Lymphoma Treated with GA101 (RO5072759) in Combination With Chop Chemotherapy

  12/15/2011 - 12/15/2014

  Document ID: GAO4915g

  Sponsor: Genentech, Inc.

• 4.

  Leo Gordon; Brandon Miller

  Prot#NU 11H01: A Phase II Trial of Sequential SGN-35 Therapy With Adriamycin, Vinblastine, and Dacarbazine (S-AVD) for Older Patients with Untreated Hodgkin Lymphoma

  11/8/2011 - 11/8/2014

  Document ID: NU11H01

  Sponsor: Seattle Genetics, Inc.

• 5.

  Shuo Ma; Olga Frankfurt; Leo Gordon; Steven Rosen; Jane Norma Winter

  Prot# OFT114699//NU 10H06: A Phase 2 Trial of Alemtuzumab-Ofatumumab Combination in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia

  4/21/2011 - 4/21/2014

  Document ID: OFT114699//NU10H06

  Sponsor: GlaxoSmithKline plc

• 6.

  Leo Gordon; Hugh Anderson

  Prot#PLX 108-03: A Phase 2 Safety and Efficacy Study of Orally Administered PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma

  1/21/2011 - 1/21/2014

  Document ID: PLX108-03

  Sponsor: Plexxikon Inc.

• 7.

  Andrew Evens; Leo Gordon; Adam Petrich

  Prot# CC-5013-DLC-001: A Phase 2/3 Mulitcenter, Randomized Open-Label Stuyd to Compare the Efficacy and Safety of Lenalidomide (Revlimid®) Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

  10/26/2010 - 10/26/2013

  Document ID: CC-5013-DLC-001

  Sponsor: Celgene Corporation

• 8.

  Leo Gordon; Hugh Anderson

  Prot#CC-5013-MCL-001: A Phase II Multicenter, Single-Arm, Open-Label Study to Determine the Efficacy and Safety of Single-Agent, Lenalidomide (Revlimid®) in Patients with Mantle Cell NHL who Have Relapsed or Progressed After Treatment with Bortezomib or are Refractory to Bortezomib. The "EMERGE" Trial.

  10/15/2010 - 10/15/2013

  Document ID: CC-5013-MCL-001

  Sponsor: Celgene Corporation

• 9.

  Leo Gordon; Amareshwar Singh

  Targeted ATRA Nanodisks for Mantle Cell Lymphoma

  10/28/2009 - 6/30/2010

  Document ID: Agmtsigned10/28/09//R43CA141904

  Sponsor: Lypro Biosciences, Inc.

• 10.

  Leo Gordon

  Prot# TED6828: An Open-Label Multi-Dose-Escalation, Safety and Pharmacokinetic Study of SAR3419 Administered as a Single Agent by Intravenous Infusion Every 3 Weeks in Patients with Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

  11/20/2008 - 11/20/2011

  Document ID: TED6828

  Sponsor: sanofi-aventis U.S. LLC

• 11.

  Andrew Evens; Leo Gordon; Borko Jovanovic; Richard Longnecker

  Discovery of New Treatment Options for EBV-Associated Lymphoma and PTLD

  7/14/2008 - 5/31/2013

  Document ID: R01CA133063

  Sponsor: National Cancer Institute

• 12.

  Leo Gordon

  Therapeutic Strategies Targeting Apoptotic Pathways in Hodgkin and Non-Hodgkin's Lymphoma

  7/1/2008 - 6/30/2009

  Document ID: AwardLetter5/8/2008

  Sponsor: Amgen, Inc.

• 13.

  Leo Gordon

  Prot# CT-2007-01: Phase II Safety and Efficacy Study of the Monoclonal Antibody CT-011 in Patients with Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation

  12/22/2007 - 12/22/2010

  Document ID: CT-2007-01

  Sponsor: CureTech Ltd.

• 14.

  Robert Treat Chatterton Jr; Steven Rosen; Vadim Backman; Charles Bennett; Raymond Bergan; William Catalona; David Cella; Amy Chadburn; Debabrata Chakravarti; Teng-Leong Chew; Joan Chmiel; Seung Choi; Charles Clevenger; Susan Crawford; John Crispino; Lynn Doglio; Pan Du; Elizabeth Eklund; Pamela Focia; Charles Lewis Goolsby; Leo Gordon; Kathleen Janee Green; Arabela Grigorescu; Elizabeth Hahn; Curt Horvath; Chiang-Ching Huang; Nadereh Jafari; Jonathan Jones; Borko Jovanovic; Seema Khan; Warren Kibbe; Hiroaki Kiyokawa; Timothy Michael Kuzel; Carole LaBonne; Chung Lee; Lin Li; Jonathan Licht; Simon Lin; Richard Longnecker; Andreas Matouschek; Alfonso Mondragon; Thomas O'Halloran; Boris Pasche; Jason Pattie; Jill Pelling; Michael Pins; Leonidas Platanias; Izolda Popova; Alfred Rademaker; Julian Schink; Denise Scholtens; Juned Siddique; William Small Jr; Bonnie Spring; Sharon Stack; Martin Tallman; Warren Tourtellotte; Thomas Volpe; Jamie Hayden Von Roenn; Edward Vonesh; Lynne Wagner; Zdzislaw Wawrzak; Jonathan Widom; Gayle Woloschak; Ximing Yang; Susan Yount; Lihua Zhu; Daniel Erickson; Angela Fought; Veronica Jackson; Dachao Liu; Carolyn Pelham; Sarah Rosenbloom; Janel Washington; Kimberly Webster; Kathleen Yost; Yuan Zhong

  The Robert H. Lurie Comprehensive Cancer Center

  9/14/2007 - 7/31/2013

  Document ID: 3P30CA060553-18S3

  Sponsor: National Cancer Institute

• 15.

  Steven Rosen; Vadim Backman; Charles Bennett; Al Benson III; Raymond Bergan; William Catalona; Debabrata Chakravarti; Teng-Leong Chew; Joan Chmiel; Charles Clevenger; Susan Crawford; Lynn Doglio; Elizabeth Eklund; Pamela Focia; Susan Gapstur; Charles Lewis Goolsby; Leo Gordon; Kathleen Janee Green; Curt Horvath; Seema Khan; Hiroaki Kiyokawa; Timothy Michael Kuzel; Carole LaBonne; Chung Lee; Jonathan Licht; Richard Longnecker; Andreas Matouschek; Alfonso Mondragon; Thomas O'Halloran; Boris Pasche; Jill Pelling; Michael Pins; Alfred Rademaker; Mary Rundell; Julian Schink; Bonnie Spring; Sharon Stack; Martin Tallman; Warren Tourtellotte; Thomas Volpe; Jamie Hayden Von Roenn; Jonathan Widom; Gayle Woloschak; Teresa Woodruff

  The Robert H. Lurie Comprehensive Cancer Center

  9/14/2007 - 7/31/2012

  Document ID: 3P30CA060553-18S3

  Sponsor: National Cancer Institute

• 16.

  Jeffrey Raizer; Al Benson III; James Brandman; Mary Cianfrocca; Andrew Evens; Olga Frankfurt; Leo Gordon; William Gradishar; Virginia Georgia Kaklamani; Timothy Michael Kuzel; Mary Frances Mulcahy; Jyoti Patel; Steven Rosen; Martin Tallman; Jane Norma Winter

  Prot# H3E-US-1012: A Pharmacokinetic Study of Pemetrexed in the Cerebrospinal Fluid of Patients with Leptomeningeal Metastases (NU prot # NU 06C2)

  12/22/2006

  Document ID: H3E-US-1012

  Sponsor: Lilly Research Laboratories

• 17.

  Andrew Evens; Olga Frankfurt; Leo Gordon; Timothy Michael Kuzel; Jayesh Mehta; Steven Rosen; Seema Singhal; Martin Tallman; Jane Norma Winter

  Prot# NU 06H2: A Multicenter Phase II Study Incorporating DOXIL® and Rituximab into the Magrath Regimen for HIV-Negative and HIV-Positive Patients with Newly Diagnosed Burkitt's and Burkitt-like Lymphoma

  8/3/2006 - 4/1/2012

  Document ID: NU06H2

  Sponsor: Ortho Biotech Clinical Affairs, LLC

• 18.

  Leo Gordon; Al Benson III; Andrew Evens; Richard Longnecker; Martin Tallman; Jane Norma Winter

  Prot# NU 02Z5: Determination of Epstein Barr Virus (EBV) Load Before and After Treatment with Tyrosine Kinase or Proteasome Inhibitors: A Pilot Study

  7/18/2006

  Document ID: NU02Z5

  Sponsor: Millennium Pharmaceuticals, Inc.

• 19.

  Andrew Evens; Olga Frankfurt; Leo Gordon; Timothy Michael Kuzel; Jayesh Mehta; Steven Rosen; Seema Singhal; Martin Tallman; Jane Norma Winter

  Prot# X05211: A Phase II Trial of Combination Bortezomib and Rituximab as Front-Line Therapy for Low-Grade Non-Hodgkin's Lymphoma (NU Prot# NU 06H1)

  6/29/2006

  Document ID: X05211

  Sponsor: Millennium Pharmaceuticals, Inc.

• 20.

  Jane Norma Winter; Andrew Evens; Leo Gordon

  Prot# X05195: A Phase I/II Trial of Combined Weekly Bortezomib (VELCADE®) and Y-90-Ibritumomab Tiuxetan (Zevalin) in Patients with Relapsed or Refractory Follicular Lymphoma (NU Prot# NU 05H9)

  6/23/2006

  Document ID: X05195

  Sponsor: Millennium Pharmaceuticals, Inc.

• 21.

  Leo Gordon

  Multi-Institutional Non Hodgkin's Lymphoma Outcomes Project within the National Comprehensive Cancer Network

  2/6/2006 - 12/31/2012

  Document ID: Agreementdated5/29/09

  Sponsor: National Comprehensive Cancer Network

• 22.

  Andrew Evens; Elizabeth Eklund; Leo Gordon; Timothy Michael Kuzel; Jayesh Mehta; Leonidas Platanias; Steven Rosen; Seema Singhal; Martin Tallman; Stephanie Williams; Jane Norma Winter

  Prot# B9E-US-X446: A Phase I/II Trial of Combination Bortezomib (VELCADE®) and Gemcitabine Therapy for Patients with Relapsed or Refractory Aggressive B- and T -Cell Non-Hodgkin's Lymphoma (NU Prot# NU 04H4)

  9/12/2005

  Document ID: B9E-US-X446/NU04H4

  Sponsor: Eli Lilly and Company

• 23.

  Andrew Evens; Elizabeth Eklund; Leo Gordon; Timothy Michael Kuzel; Jayesh Mehta; Leonidas Platanias; Steven Rosen; Seema Singhal; Martin Tallman; Stephanie Williams; Jane Norma Winter

  Prot# VEL-03-082: A Phase I/II Trial of Combination Bortezomib (VELCADE®) and Gemcitabine Therapy for Patients with Relapsed or Refractory Aggressive B- and T -Cell Non-Hodgkin's Lymphoma (NU Prot# NU 04H4)

  7/8/2005

  Document ID: VEL-03-082/NU04H4

  Sponsor: Millennium Pharmaceuticals, Inc.

• 24.

  Andrew Evens; Leo Gordon; Borko Jovanovic; Steven Rosen

  CAREER: Targeting the Mitochondria to Treat Lymphoma and Myeloma

  6/9/2005 - 5/31/2010

  Document ID: K23CA109613

  Sponsor: National Cancer Institute

• 25.

  Jeffrey Raizer; James Chandler; Andrew Evens; Leo Gordon; Robert Hanlon; Maryanne Hoffman Marymount; Robert Levy; Sean Salehi; Jane Norma Winter

  Prot# NU MSK03C1: A Pilot Study of Combined Immunochemotherapy Followed by Reduced Dose RT for Patients with Newly Diagnosed PCNSL (Primary Central Nervous System Lymphoma)

  7/13/2004

  Document ID: NUMSK03C1

  Sponsor: Memorial Sloan-Kettering Cancer Center

• 26.

  Al Benson III; Martin Tallman; Athanassios Argiris; Leo Gordon; William Gradishar; Timothy Michael Kuzel; Mark Talamonti; Jamie Hayden Von Roenn; Jane Norma Winter

  Eastern Cooperative Oncology Group Clinical Trials

  6/1/2004 - 4/30/2010

  Document ID: U10CA017145

  Sponsor: National Cancer Institute

• 27.

  Leo Gordon; Andrew Evens; Lisa Baddi; Punit Chadha; John Eklund; Olga Frankfurt; Virginia Georgia Kaklamani; Lisa Sokolowicz; Anaadriana Zakarija

  Prot# PSIND011: Mltctr Phz 1-2 Trial to Evaluate E&S of IDEC-Y2B8 (Zevalin) Radioimmunotherapy in Low-Grade, Follicular or Transformed B-Cell Non-Hodgkin's Lymphoma Patients Following Initial Response & Subsequent Relapse from Previous (NU Prot# UAB 0153)

  3/4/2004

  Document ID: PSIND011/NUUAB0153

  Sponsor: University of Alabama Medical School

• 28.

  Leo Gordon

  Preclinical Trial of Rituxan-Generated, Pre-Apoptotic Redox Regulation in CLL, Lymphoma & Myeloma Cell Lines

  12/18/2003

  Document ID: Agreement12/18/2003

  Sponsor: Biogen Idec Inc.

• 29.

  Leo Gordon

  Prot# F2: Prospective Collection of Data of Possible Prognostic Relevance in Patients with Follicular Lymphoma (NU Prot# NU IFLP-F2)

  12/1/2003

  Document ID: F2/NUIFLP-F2

  Sponsor: Angela Serra Association for Cancer Research

• 30.

  Charles Bennett; Athanassios Argiris; Steven Belknap; Al Benson III; Leo Gordon; Timothy Michael Kuzel; Martin Tallman; Sigmund Weitzman; Dennis West; Paul Yarnold

  Research for Adverse Drug-Events and Reports (RADAR)

  9/15/2003 - 8/31/2007

  Document ID: 5R01CA102713-02

  Sponsor: National Cancer Institute

• 31.

  Andrew Evens; Ronald Gartenhaus; Leo Gordon; Timothy Michael Kuzel; Steven Rosen; Seema Singhal; Stewart Spies; Martin Tallman; Stephanie Williams; Jane Norma Winter

  Prot# NU 02H8 (PCYC-0213): A Phase I/II Trial of Redox Regulation in Patients with Relapsed or Refractory CD20 Positive Non-Hodgkin's Lymphoma (NHL) Combining 90-Yttrium-Zevalin® and the Redox-Modulating Agent, Motexafin Gadolinium (MGd) (Prot# 106-P115)

  9/5/2003

  Document ID: NU02H8/106-P115

  Sponsor: Biogen Idec Inc.

• 32.

  Andrew Evens; Ronald Gartenhaus; Leo Gordon; Timothy Michael Kuzel; Steven Rosen; Seema Singhal; Stewart Spies; Martin Tallman; Stephanie Williams; Jane Norma Winter

  Prot# NU 02H8 (PCYC-0213): A Phase I/II Trial of Redox Regulation in Patients with Relapsed or Refractory CD20 Positive Non-Hodgkin's Lymphoma (NHL): Combining 90Yttrium-Zevalin & Redox-Modulating Agent, Motexafin Gadolinium (MGd)

  7/23/2003

  Document ID: NU02H8

  Sponsor: Pharmacyclics, Inc.

• 33.

  Leo Gordon

  Prot# 114-21: A Phase I/II Trial of IDEC-114 (Anti-CD80 Monoclonal Antibody) in Combination with Rituxan® for Patients with Relapsed or Refractory Follicular Lymphoma

  1/14/2003

  Document ID: 114-21

  Sponsor: IDEC Pharmaceuticals Corporation

• 34.

  Leo Gordon

  Prot# IDEC 114-20: A Phase I/II Trial of Anti-CD80 Monoclonal Antibody (IDEC-114) Therapy for Patients with Relapsed or Refractory Follicular Lymphoma

  4/23/2002

  Document ID: IDEC114-20

  Sponsor: IDEC Pharmaceuticals Corporation

• 35.

  Steven Rosen; David Barch; Richard Bell; Charles Bennett; Al Benson III; Raymond Bergan; Robert Treat Chatterton Jr; Rex Chisholm; Susan Cohn; James Engel; David Fishman; Peter Gann; Charles Lewis Goolsby; Leo Gordon; Philip Greenland; Philip Iannaccone; Virgil Craig Jordan; Borko Jovanovic; Warren Kibbe; James Kozlowski; Timothy Michael Kuzel; Chung Lee; Robin Leikin; Victor Levenson; Richard Longnecker; Alfonso Mondragon; Monica Morrow; Sharon Murphy; Thomas O'Halloran; Michael Pins; Alfred Rademaker; Mary Rundell; Sharon Stack; Martin Tallman; Jonathan Widom; Teresa Woodruff; Alice Wyrwicz; Weiming Yu

  The Robert H. Lurie Comprehensive Cancer Center - Administrative Core

  8/1/2001 - 7/31/2007

  Document ID: 3P30CA060553-13S3

  Sponsor: National Cancer Institute

• 36.

  Steven Rosen; Thomas Adrian; Dhugal Bedford; Serdar Bulun; William Catalona; Teng-Leong Chew; Rex Chisholm; Joan Chmiel; Susan Gapstur; Ronald Gartenhaus; David Gordon; Chiang-Ching Huang; Melina Kibbe; Nancy Krett; Anait Levenson; Andreas Matouschek; Leonidas Platanias; Boris Popov; Denise Scholtens; Warren Tourtellotte; Thomas Volpe; Timothy Volpe; Ximing Yang; David Barch; Richard Bell; Charles Bennett; Al Benson III; Raymond Bergan; Robert Treat Chatterton Jr; Susan Cohn; James Engel; David Fishman; Peter Gann; Charles Lewis Goolsby; Leo Gordon; Philip Greenland; Philip Iannaccone; Virgil Craig Jordan; Borko Jovanovic; Warren Kibbe; James Kozlowski; Timothy Michael Kuzel; Chung Lee; Robin Leikin; Victor Levenson; Richard Longnecker; Alfonso Mondragon; Monica Morrow; Sharon Murphy; Thomas O'Halloran; Michael Pins; Alfred Rademaker; Mary Rundell; Sharon Stack; Martin Tallman; Jonathan Widom; Teresa Woodruff; Alice Wyrwicz; Weiming Yu

  The Robert H. Lurie Comprehensive Cancer Center - Administrative Core

  8/1/2001 - 7/31/2007

  Document ID: 3P30CA060553-13S3

  Sponsor: National Cancer Institute

• 37.

  Steven Rosen; Leo Gordon; Mary Rundell; Susan Gapstur; Jonathan Licht; Jill Pelling; Leonidas Platanias; Teresa Woodruff

  The Robert H. Lurie Comprehensive Cancer Center - Administrative Core

  8/1/2001 - 7/31/2007

  Document ID: 3P30CA060553-13S3

  Sponsor: National Cancer Institute

• 38.

  Steven Rosen; David Barch; Richard Bell; Charles Bennett; Al Benson III; Raymond Bergan; Robert Treat Chatterton Jr; Rex Chisholm; Susan Cohn; James Engel; David Fishman; Peter Gann; Charles Lewis Goolsby; Leo Gordon; Philip Greenland; Philip Iannaccone; Virgil Craig Jordan; Borko Jovanovic; Warren Kibbe; James Kozlowski; Timothy Michael Kuzel; Chung Lee; Victor Levenson; Richard Longnecker; Alfonso Mondragon; Monica Morrow; Sharon Murphy; Thomas O'Halloran; Michael Pins; Alfred Rademaker; Mary Rundell; Sharon Stack; Martin Tallman; Jonathan Widom; Teresa Woodruff; Alice Wyrwicz; Weiming Yu

  The Robert H. Lurie Comprehensive Cancer Center - Administrative Core

  8/1/2001 - 7/31/2006

  Document ID: 3P30CA060553-13S3

  Sponsor: National Cancer Institute

• 39.

  Leo Gordon

  Protocol # NU 98H2: Phase I/II Study of Mesna, Ifosfamide, Teniposide and Weekly Taxol (MITTen) in Relapsed Lymphoma

  8/10/1999

  Document ID: NU98H2

  Sponsor: Bristol-Myers Squibb Company

• 40.

  Leo Gordon; Stewart Spies; William Spies; A Michael Zimmer

  Protocol # 106-04: A Randomized, Phase III Multicenter, Controlled Trial to Evaluate the Efficacy and Safety of IDEC-Y2B8 Radioimmunotherapy Compared to Rituxan Immunotherapy of Relapsed or Refractory Low-Grade or Follicular B-Cell Non-Hodgkin's Lymphoma

  2/16/1998

  Document ID: Protocol#106-04

  Sponsor: IDEC Pharmaceuticals Corporation

• 41.

  Leo Gordon

  A Phase I/II Clinical Trial to Evaluate the Safety and Clinical Activity of IDEC-Y2B8 Administered to Patients with B-Cell Lymphoma (IDEC-Y2B8 Protocol Number 106-03)

  7/17/1996

  Document ID: 106-03

  Sponsor: IDEC Pharmaceuticals Corporation